What's new in short bowel syndrome?
Curr Opin Clin Nutr Metab Care
; 21(4): 313-318, 2018 07.
Article
em En
| MEDLINE
| ID: mdl-29702489
ABSTRACT
PURPOSE OF REVIEW Short bowel syndrome (SBS) is a rare disease but with many complications due to intestinal failure, parenteral nutrition and underlying disease. A better prevention, comprehension and treatment could improve the outcome of these patients. RECENT FINDINGS:
Recent studies have been published on acute intestinal failure, first cause of SBS, and gives us strategy to avoid extended intestinal resection and thus SBS. There has been progress in the comprehension of intestinal adaptation, characterized by improvements in intestinal absorption, changes on hormonal secretion, development of a hyperphagia and dysbiosis of the gut microbiota. Hormonal treatment focusing on intestinal rehabilitation by promoting intestinal hyperadaptation has been proposed in patients with SBS, who require parenteral nutrition and intravenous fluids, such as glucagon-like peptide-2 (GLP-2) analog which is now recommended by the latest European Society for Clinical Nutrition and Metabolism Guidelines.SUMMARY:
Multimodal treatment of acute meseteric ischemia may avoid intestinal resection and is an effective prevention strategy for SBS. New understandings in intestinal adaptation can help us to optimize this adaptation, including with hormonal therapy. GLP-2 analog is now the treatment of reference in SBS patients with chronic intestinal failure.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Síndrome do Intestino Curto
/
Adaptação Fisiológica
/
Nutrição Parenteral
/
Peptídeo 2 Semelhante ao Glucagon
/
Intestino Delgado
Tipo de estudo:
Etiology_studies
/
Guideline
Limite:
Humans
Idioma:
En
Ano de publicação:
2018
Tipo de documento:
Article